EP1943350A4 - Procytotoxines latentes et utilisations de celles-ci - Google Patents

Procytotoxines latentes et utilisations de celles-ci

Info

Publication number
EP1943350A4
EP1943350A4 EP06825387A EP06825387A EP1943350A4 EP 1943350 A4 EP1943350 A4 EP 1943350A4 EP 06825387 A EP06825387 A EP 06825387A EP 06825387 A EP06825387 A EP 06825387A EP 1943350 A4 EP1943350 A4 EP 1943350A4
Authority
EP
European Patent Office
Prior art keywords
procytotoxins
latent
latent procytotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06825387A
Other languages
German (de)
English (en)
Other versions
EP1943350A2 (fr
Inventor
Thomas E Wagner
Xianzhang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenville Hospital System
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Publication of EP1943350A2 publication Critical patent/EP1943350A2/fr
Publication of EP1943350A4 publication Critical patent/EP1943350A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP06825387A 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci Withdrawn EP1943350A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72351105P 2005-10-04 2005-10-04
PCT/US2006/038584 WO2007044321A2 (fr) 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci

Publications (2)

Publication Number Publication Date
EP1943350A2 EP1943350A2 (fr) 2008-07-16
EP1943350A4 true EP1943350A4 (fr) 2009-06-17

Family

ID=37943314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06825387A Withdrawn EP1943350A4 (fr) 2005-10-04 2006-09-29 Procytotoxines latentes et utilisations de celles-ci

Country Status (5)

Country Link
EP (1) EP1943350A4 (fr)
JP (1) JP2009510166A (fr)
AU (1) AU2006302587A1 (fr)
CA (1) CA2624802A1 (fr)
WO (1) WO2007044321A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004694A1 (fr) * 2012-06-26 2014-01-03 Massachusetts Institute Of Technology Dissimulation réversible de protéines formant des pores pour distribution macromoléculaire
CN103275911B (zh) * 2013-01-02 2015-11-25 温州医学院 一种含有pET-28a(+)-protein400重组质粒的大肠杆菌及其制备方法
CA2917056C (fr) * 2013-06-27 2020-03-24 Rutgers, The State University Of New Jersey Traitement et diagnostic d'une maladie oculaire
CN106632633B (zh) * 2016-11-24 2020-03-20 浙江海洋大学 一种绿侧花海葵抗肿瘤寡肽及其用途
WO2021071419A1 (fr) * 2019-10-11 2021-04-15 Wai Sun Nyunt Protéine de vibrio cholerae destinée à être utilisée contre le cancer
CN112724258A (zh) * 2019-10-29 2021-04-30 深圳市第二人民医院 靶向杀死癌细胞的复合多肽分子及其制备方法
EP4182334A4 (fr) * 2020-07-17 2024-10-16 Univ Western Australia Compositions et méthodes de traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045736A1 (en) * 2001-05-09 2002-04-18 Xianxhang Yu Lytic peptide prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100551D0 (en) * 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045736A1 (en) * 2001-05-09 2002-04-18 Xianxhang Yu Lytic peptide prodrugs

Also Published As

Publication number Publication date
WO2007044321A3 (fr) 2007-07-05
JP2009510166A (ja) 2009-03-12
EP1943350A2 (fr) 2008-07-16
CA2624802A1 (fr) 2007-04-19
AU2006302587A1 (en) 2007-04-19
WO2007044321A2 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
IL222922A (en) Antibodies against neurophilin-1 and their use
EP1802588A4 (fr) Amino-pyrimidones substitues et utilisation de ceux-ci
HK1119441A1 (en) Toner
GB0512940D0 (en) Compounds and their use
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
EP1944655A4 (fr) Toner
IL184024A0 (en) Irta-5 antibodies and their uses
IL189609A0 (en) 4-substituted pyrrolidin-2-ones and their use
EP1962142A4 (fr) Toner
IL179497A0 (en) Carboranylporphyrins and uses thereof
GB0520743D0 (en) Compounds and their use
EP1893569A4 (fr) Composes sulfonamide et leurs utilisations
IL189252A0 (en) Dihydroxyanthraquinones and their use
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP1912921A4 (fr) Composes a base de tetraazaporphyrine et leurs utilisations
GB0502979D0 (en) Biomarkers and uses thereof
EP1921066A4 (fr) Composé de pyridylphénol et son utilisation
IL185223A0 (en) Compounds and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
EP1943350A4 (fr) Procytotoxines latentes et utilisations de celles-ci
EP1887432A4 (fr) Toner et liant de toner
GB0520935D0 (en) Integrated processor-template-system and project
GB0502978D0 (en) Biomarkers and uses thereof
GB0517239D0 (en) Geogrotren-mk1-system and project
GB0517240D0 (en) Chronorotron mk1-system and project

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080408

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090520

17Q First examination report despatched

Effective date: 20090907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100318